The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).
 
Linda R. Mileshkin
No Relationships to Disclose
 
Kathleen N. Moore
Honoraria - Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Eisai; Genentech/Roche; Immunogen; Merck; Mersana (Inst); Myriad Genetics; Pfizer/EMD Serono; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
 
Elizabeth Barnes
No Relationships to Disclose
 
Val Gebski
No Relationships to Disclose
 
Kailash Narayan
No Relationships to Disclose
 
Nathan Bradshaw
No Relationships to Disclose
 
Yeh Chen Lee
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Katrina Diamante
No Relationships to Disclose
 
Anthony W. Fyles
No Relationships to Disclose
 
William Small
Honoraria - Carl Zeiss Meditec; Varian Medical Systems
Consulting or Advisory Role - Merck; Varian Medical Systems
Research Funding - Carl Zeiss Meditec (Inst)
Travel, Accommodations, Expenses - Carl Zeiss Meditec
 
David K. Gaffney
Consulting or Advisory Role - Merck
Research Funding - Elekta
 
Pearly Khaw
No Relationships to Disclose
 
Susan Brooks
No Relationships to Disclose
 
J Spencer Thompson
Travel, Accommodations, Expenses - Mevion Medical Systems
 
Warner King Huh
Consulting or Advisory Role - DYSIS Medical; LI-COR Biosciences
Expert Testimony - Intuitive Surgical; Johnson & Johnson
Other Relationship - Inovio Pharmaceuticals
 
Matthew Carlson
No Relationships to Disclose
 
Cara Amanda Mathews
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Deciphera (Inst); Moderna Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seattle Genetics (Inst); Syros Pharmaceuticals (Inst); Tesaro/GSK (Inst)
 
Danny Rischin
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Kura Oncology (Inst); Merck (Inst); Merck KGaA (Inst); Regeneron (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline; Merck; Regeneron; Sanofi
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoID; Clovis Oncology; Deciphera; Eisai; Elevar Therapeutics; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Starton Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoCare; ChemoID; Clovis Oncology; Deciphera; Eisai; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Sorrento Therapeutics; Sorrento Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)